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Background: Varicose veins are a common vascular disease in elderly patients. Both endovascular laser
ablation (EVLA) and radiofrequency ablation (RFA) are reported to have good technical, clinical, and
patient-reported outcomes for the treatment of varicose veins. We did not ﬁnd any reports on treating
elderly patients with endovascular ablation procedures in the literature. The aim of this study was to
determine whether endovenous thermal ablation techniques are safe and effective in treating elderly
patients with varicose veins.
Method: A retrospective analysis of 57 EVLA cases and 46 RFA cases was conducted at a single center.
Patients in the 65e88-year age group were assessed for postoperative pain, hematoma, thrombophle-
bitis, hyperpigmentation, wound infection, and skin burn.
Results: Minor complications identiﬁed in the studied patients were hematoma (2.9%), thrombophlebitis
(5.8%), hyperpigmentation (8.7%), wound infection (4.9%), and skin burn (1%). In the RFA group, 38 pa-
tients (83%) had no need for oral analgesic tablets on postoperative Day 3. In the EVLA group, 25 patients
(44%) had no need for oral analgesic tablets on postoperative Day 3. Two patients in the EVLA group
needed a secondary intervention due to recurrent vein issues. There were no major complications in
either group.
Conclusion: The outcomes for our older patients who underwent endovascular ablation therapy were
comparable to other studies performed with the general population. Our results show that both EVLA
and RFA are feasible, safe, and well-tolerated by elderly patients.
Copyright © 2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
The prevalence of varicose veins ranges from 1% to 73% in
women and 2% to 56% in men1. Traditional surgical methods for
treating varicose veins, including saphenofemoral junction (SFJ)
ligation, great saphenous vein (GSV) stripping, and multiple phle-
bectomies, have been the accepted treatment of choice for almost a
century2. However, traditional surgical methods to treat varicose
veins are associatedwith signiﬁcant complications, high recurrencere that they have no conﬂicts
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tric Emergency & Critical Care Merates, and some patient dissatisfaction. In a randomized trial of SFJ
ligation methods for primary saphenous incompetence, the 2-year
clinical recurrence rate was 33% and Doppler ultrasound-proven
recurrence was up to 22%3. About 10 years ago, new alternatives
to these surgical treatments [endovascular laser ablation (EVLA)
and radiofrequency ablation (RFA)] were developed, which are
having a major impact on management choices4.
Endovenous thermal ablation techniques, which include RFA or
EVLA, are less invasive varicose vein treatment alternatives to
stripping the incompetent GSV and the results are as effective as
the traditional stripping surgery5. The largest meta-analysis
examined 64 eligible studies and showed that the success rate
was higher in patients undergoing endovascular ablation therapy
than in patients undergoing traditional surgery3. According to
several randomized trials, patients who underwent endovenous
thermal ablation surgery had shorter recovery times beforedicine. Published by Elsevier Taiwan LLC. All rights reserved.
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traditional stripping surgery6e8.
The aim of this study was to evaluate whether endovenous
thermal ablation techniques are safe and efﬁcient in treating cases
of varicose veins in elderly patients.
2. Patients and methods
From December 2009 to August 2011, 103 patients between 65
and 88 years of age were enrolled for the study. Of these, 46 pa-
tients (63 limbs) underwent treatment for GSV with RFA tech-
niques using the ClosureFast RF catheter and 57 patients (68 limbs)
underwent EVLA using a 980-nm wavelength laser. The study was
retrospective and conducted by two surgeons at Mackay Memorial
Hospital. Of the 103 patients, 70 were women and 33 were men.
Comorbidities were mild, with the most frequent being hyperten-
sion in 15 patients (14.6%), cardiovascular disease in two patients
(1.9%), osteoarthritis of the knee joint in six patients (5.8%), and
diabetes mellitus in 12 patients (11.7%).
2.1. Data analyses
All data were analyzed using the Statistical Package for the So-
cial Sciences version 14.0 (SPSS, Inc., Chicago, IL, USA). Descriptive
statistics were used to summarize the demographic characteristics
of patients. Fisher's exact test and Chi-square tests were used for
categorical data. Data were presented as mean or percentages, and
p < 0.05 was considered statistically signiﬁcant.Table 1
Demographics and treatment details of the study patients (N ¼ 103).
Variables Total RFA
(n ¼ 46)
EVLA
(n ¼ 57)
c2/t p
N (%) n (%) n (%)
Sex 0.91a 0.34
Male 33 (32) 17 (37) 16 (28)
Female 70 (68) 29 (63) 41 (72)
Age (y) 0.88 0.38
mean ± SD 67.0 ± 5.12 66.3 ± 5.39 67.6 ± 5.02
Min 65 65 65
Max 88 83 88
CEAP class 4.91a 0.43
C1 0 0 0
C2 36 16 20
C3 24 10 14
C4 21 8 13
C5 12 6 6
C6 10 6 4
Postoperative complications
Wound infection 0.49a 0.48
Yes 5 3 2
No 98 43 55
Hematoma 0.16a 0.69
Yes 3 1 2
No 100 45 55
Thrombophlebitis 0.33a 0.58
Yes 6 2 4
No 97 44 53
Paresthesia 0.13a 0.72
Yes 10 5 5
No 93 41 52
Hyperpigmentation 0.00a 0.99
Yes 9 4 5
No 94 42 52
Skin burn 0.81a 0.37
Yes 1 0 1
No 102 46 56
CEAP ¼ ClinicaleEtiologyeAnatomyePathophysiology; EVLA ¼ endovascular laser
ablation; RFA ¼ radiofrequency ablation; SD ¼ standard deviation.
a Fisher's exact test.2.2. Ethic statement
This study was approved by the Institutional Review Board of
Mackay Memorial Hospital (13MMHIS052). The Clin-
icaleEtiologyeAnatomyePathophysiology (CEAP) clinical class
distribution in our patients was mostly C2 (n ¼ 36 patients) and C3
(n ¼ 24 patients; Table 1).
In the preoperative preparation, all patients underwent the
plethysmography examination to rule out deep vein thrombosis.
The patients with cardiovascular disease who used anticoagulation
drugs such as aspirin were required to stop their use at least 7 days
before the operation. Symptomatic varicose veins and incompe-
tence of the GSV were conﬁrmed by duplex ultrasound
examination.
In the EVLA group, 40 patients (70%) received local anesthesia
[subcutaneous standard tumescent solution; 50 mL 1% lidocaine
with 1:200,000 adrenaline (epinephrine) in 1000 mL normal sa-
line], which was inﬁltrated along the length of the vein with or
without ultrasound guidance; 17 (30%) patients in the group
received general or spinal anesthesia accompanied by tumescent
inﬁltration. In the VNUS ClosureFast radiofrequency group, local
anesthesia was administered in seven (15%) patients; 39 (85%)
patients in the group received general or spinal anesthesia
accompanied by tumescent inﬁltration along the saphenous vein
with ultrasound guidance. Tumescent solution inﬁltration can
protect against thermal injury to the soft tissue and compress the
treated vein to improve contact with the RFA catheter or laser ﬁber,
thereby enhancing the ablation result.
The laser ﬁber or RFA catheter was introduced into the GSV
using the cut-down method, creating an incisional wound about
1 cm in length above the malleolus bone. With ultrasound guid-
ance, the laser ﬁber tip or RFA catheter was inserted about 2 cm
below the SFJ. Tumescent solution was inﬁltrated along the length
of the treated vein with or without ultrasound guidance. In the
EVLA group, the laser ﬁber was continuously withdrawn at a speed
of 1 cm/second, delivering energy greater than 60 J/cm to the vein
wall. The ablation power was set to 15 W at the thigh level, 12 W at
the knee-joint level, and 8 W at the lower leg level. In the RFA
group, the catheter treated a 7-cm vein segment in one 20-second
energy cycle. The treatment temperature was set to 110C at the
thigh level and 95C at the knee-joint level down to the lower leg.
The ablation procedure was performed on an outpatient basis for
40 (70%) patients in the EVLA group and seven (15%) patients in the
RFA group, all receiving only local anesthesia. Seventeen (30%)
patients in the EVLA group and 39 (85%) patients in the RFA group
received general or spinal anesthesia, with all patients being dis-
charged from the hospital the 2nd day after the operation.
All patients were followed after the operation for 9e29 months,
with a mean time of 14.5 months. Patients were evaluated at
postoperative Day 3, at 1 week, at 1month, at 3months, and then at
3-month intervals. From the chart records, we collected data about
analgesic tablet use, hematomas, skin burns, wound infections,
thrombophlebitis, paresthesia, or hyperpigmentation.3. Results
From December 2009 to August 2011, 103 patients received
either EVLA or RFA, including 70 women and 33 men, with a mean
age of 67 years. The study enrolled 103 patients (131 legs) in the
“over 65” age group. The EVLA group consisted of 68 legs (41
women and 16 men; mean age of patients: 67.6; range: 65e88
years). The RFA group consisted of 63 legs (29 women and 17 men;
mean age of patients: 66.3; range: 65e83 years). Themedian follow
up was 14.5 months and ranged from 9 to 29 months.
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In the RFA group versus the EVLA group, the patient numbers were
16 versus 20 at C2,10 versus 14 at C3, 8 versus 13 at C4, 6 versus 6 at
C5, and 6 versus 4 in C6, respectively. The baseline characteristics of
the patients over the age of 65 were comparable between the two
procedures as can be seen in Table 1. Ten patients categorized as
CEAP clinical class 6 had active venous ulcers that healed within 4
weeks. Thus, the ulcer healing rate in this study was 100%.
The closure rate varied between the RFA- and EVLA-treated
veins. Although there was no recurrence in the RFA group, two
patients in the EVLA group suffered recurrences at 20 and 26
months after their procedures. Duplex ultrasound showed reﬂux at
the SFJ and patency of the saphenous vein; 96% closure rate was
achieved in the EVLA-treated group.
3.1. Postoperative pain and analgesic tablet use
The postprocedural pain following the EVLAs and RFAs was
mild. Following the completion of the procedure, the patients
routinely received oral analgesic tablets (diclofenac potassium
25 mg) for 3 days. Patients who underwent an RFA reported less
pain than those undergoing an EVLA. In the RFA group, 38 patients
(83%) had no need for oral analgesic tablets on postoperative Day 3.
In the EVLA group, 25 patients (44%) had no need for oral analgesic
tablets on postoperative Day 3.
3.2. Daily activities
In the chart records, approximately two thirds of the patients
returned to normal activities within 3 days: 35 patients (61%) in the
EVLA group and 33 patients (72%) in the RFA group. In terms of
returning to work, data were available for 28 patients in the EVLA
group and for 32 patients in the RFA group: 10 patients in the EVLA
group (36%) and 12 patients in the RFA group (38%) returned to
workwithin 3 days, and 20 patients (71%) in the EVLA group and 25
patients (78%) in the RFA group returned to work within 7 days.
3.3. Complications
No major complications were observed in either group. Minor
complications occurred, including wound infection (4.9%; 2 in EVLA
and 3 in RFA), hematoma (2.9%; 2 in EVLA and 1 in RFA), throm-
bophlebitis (5.8%; 4 in EVLA and 2 in RFA), paresthesia (9.7%; 5 in
EVLA and 5 in RFA), skin hyperpigmentation (8.7%; 5 in EVLA and 4
in RFA), and skin burn (1%; only 1 patient in the EVLA group).
Table 1 presents the minor complications that occurred in these
patients.
Statistically signiﬁcant difference in complications was not
observed in either group.
4. Discussion
Less postoperative pain and an early return to normal activities
are the main factors that increase the patients' willingness to un-
dergo the endovascular ablation procedures. The results in our
study were similar to the ﬁndings in other studies that have re-
ported less postprocedural pain9,10. In the RFA group, 38 patients
(83%) had no need for oral analgesic tablets on postoperative Day 3.
In the EVLA group, 25 patients (44%) had no need for oral analgesic
tablets on postoperative Day 3. The possible reason for less pain
following RFA may be that the controlled temperature and
segmental ablation technique of VNUS ClosureFast reduce the
number of vein wall perforations and the extravasation of blood
into the tissue11. In both the animal models and human studies, thelaser ablation procedure has been shown to cause vessel perfora-
tion due to the use of high temperatures12,13.
RFA and EVLA are different modes for delivering energy to the
vein wall. The endovenous laser ﬁber tip achieves temperatures up
to 100C5. Using a power setting of 10e15 W, the aim of the laser
ﬁber is to deliver energy greater than 60 J/cm to the vein wall. As
the laser ﬁber is continuously withdrawn, the heat collapses the
vein. The RFA catheter allows for segmental ablation in which this
catheter treats a 7-cm vein segment in one 20-second energy cycle.
The whole circumference of the vein wall is heated conductively by
a 7-cm coil at the distal end of the catheter, causing endovenous
temperatures ranging from 85C to 110C14.
Because the EVLA laser beam's high temperature is regulated by
the energy setting as compared with RFA in which the actual
temperature is controlled, EVLA is generally associated with vein
wall perforations15,16. Consequently, EVLA is associated with more
treatment-related pain and indurations during the patient recovery
phase as compared with RFA17. The great saphenous nerve is
adherent to the GSV in the distal limb. Injury to the nerve in this
area was the same in both groups, with ﬁve patients experiencing
paresthesia in each group. Limiting the treatment to the above-
knee segment can signiﬁcantly decrease nerve injury rates14. One
patient observed skin burn on the 3rd day after the EVLA procedure.
Following debridement, the wound healed in 4 weeks. Skin burns
may be due to insufﬁcient tumescent inﬁltration beneath the skin
or the laser ﬁber in the saphenous vein is too close to skin, causing
skin injury during the ablation procedure. These injuries can be
avoided by following ultrasound guidance for the tumescent in-
jection. Thrombophlebitis and hyperpigmentation may occur as a
result of residual blood trapped within the veins14. Four patients in
the EVLA group and two patients in the RFA group suffered from
thrombophlebitis, but it spontaneously subsided for all of them
about 1 month later.
Two patients in the EVLA group suffered recurrences at 20 and
26 months after the procedure, respectively. Duplex ultrasound
showed reﬂux at the SFJ and patency of the saphenous vein.
Another RFA procedure was performed along with high ligation of
the SFJ in the patients who experienced recurrence.
The primary closure rates of this study were not the same as
those in previous studies. In 2005, Puggioni and colleagues
compared RFA with EVLA in terms of efﬁcacy and complication
rates, and found that therewas no statistically signiﬁcant difference
in the immediate success rates between the groups (96% for RFA
and 100% for EVLA)18. In 2006, Almeida and Raines compared EVLA-
and RFA-treated limbs and reported primary closure rates of 92% for
the EVLA-treated veins and 85% for the RFA-treated veins. This
suggested a statistically signiﬁcant advantage for EVLA in terms of
immediate closures. The closure rates in this study were 100% and
96% for the RFA- and the EVLA-treated groups, respectively19.
The low primary closure rate in the study by Almeida and Raines
may be due to their use of an early generation (ordinary) radio-
frequency machine that was not a segmental ablation device and
only provided a low temperature (85C). Its prong-like catheter
structure only expanded to a maximum of 8 mm and used a
continuous pull-back technique at speeds of 2e3 cm/minute. In
2006, Dunn and co-workers reported on 85 limbs treated with RFA
at a high-temperature setting of 90C and a pull-back speed of
5e6 cm/minute. The overall success rate in their studywas 88%. The
primary closure rate was related to the temperature set point and
pull-back rate20. The new generation of radiofrequency (VNUS
ClosureFast) devices introduced in 2006 uses a new catheter that
allows for segmental ablation as opposed to continuous pull back,
works quickly (20 seconds for 7-cm segment), operates at high
temperatures ranging from 110 to 120C, and delivers stationary
energy14.
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ElKaffas et al (paresthesia in 10%, thrombophlebitis in 6.6%, and
hematoma in 3.3%)21, the results of our study were comparable to
the studies performed with the general population.
A limitation of this study was that no data were collected
regarding the venous occlusion rate after both endovascular abla-
tion procedures. Duplex ultrasound was performed for all unless a
patient presented with symptoms suspicious of recurrence.5. Conclusion
The advantages of endovascular ablation are lower incidence of
complications, shorter postintervention hospital stays, less post-
operative pain, and earlier return to normal physical activities. Our
study showed that postoperative pain and adverse events did not
occur more frequently with elderly patients than was indicated by
other clinical studies performed with a general age group.
For elderly patients over the age of 65, assuming their physical
condition allows for ambulation after the procedure and that
postoperative follow up is available, our research veriﬁed that
endovascular ablation techniques, such as EVLA and RFA, are safe,
efﬁcient, and well-tolerated as treatments for varicose veins.
However, for the deﬁnitive conclusion on efﬁcacy between
endovascular therapies in elderly patients, more long-term ran-
domized clinical trials are needed.References
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